Xeris Biopharma Holdings (XERS) Tax Provisions (2022 - 2024)

Xeris Biopharma Holdings (XERS) has reported Tax Provisions for 3 consecutive years, with -$3.3 million the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Tax Provisions fell 883.43% year-over-year to -$3.3 million; the trailing twelve-month figure through Jun 2025 stood at -$3.3 million (down 789.63% YoY), and the FY2024 full-year result was -$2.3 million, down 81.59% from the prior year.
• Tax Provisions retreated to -$3.3 million in Q3 2024 per XERS's latest filing, from $749000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $749000.0 in Q2 2024 and bottomed at -$3.3 million in Q3 2024.
• Historically, Tax Provisions has averaged -$494100.0 across 3 years, with a median of -$338500.0 in 2022.
• The widest YoY moves for Tax Provisions: up 210.96% in 2024, down 883.43% in 2024.
• Over 3 years, Tax Provisions stood at -$338000.0 in 2022, then jumped by 30.18% to -$236000.0 in 2023, then slumped by 1308.47% to -$3.3 million in 2024.
• According to Business Quant data, Tax Provisions over the past three periods registered -$3.3 million, $749000.0, and $307000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.